Vimpat is a drug approved for adjunctive treatment of partial epileptic seizures with or without secondary generalisation in adults over 16 years. The drug has been studied as adjunctive treatment to antiepileptic drugs compared with placebo and is not compared to an active comparator. In approximately 20 % of the examined patients Vimpat half’s the number of seizures.
Side effects such as dizziness, nausea, vomiting, headache and doubled vision is seen. Vimpat causes a dose related PR-elongation of 5-9 msek and are contraindicated in 2. and 3. degree AV-block.
It is approximately 6 times as expensive as other drugs normally used in treatment of partial epilepsy.
IRF states, that Vimpat has an effect on the same level as other antiepileptic drugs indicated as adjunctive treatment in patients that did not respond to mono therapy. Because of the price, Vimpat should only be used when cheaper alternatives do not have any effect.
Vimpat was marketed on January 12th 2009 and is under the rules of general reimbursement.